Axsome Therapeutics, Inc. (LON:0HKF)

Market Cap	3.86B
Revenue (ttm)	361.32M
Net Income (ttm)	-180.21M
Shares Out	n/a
EPS (ttm)	-3.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,455
Average Volume	1,766
Open	106.12
Previous Close	102.93
Day's Range	102.57 - 107.04
52-Week Range	73.05 - 141.00
Beta	n/a
RSI	47.11
Earnings Date	Aug 4, 2025

About Theseus Pharmaceuticals

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 683
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HKF

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.